|
Aug 28
|
MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
|
|
May 8
|
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
|
|
May 7
|
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
|
|
Apr 10
|
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
|
|
Mar 15
|
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
|
|
Mar 11
|
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
|
|
Mar 10
|
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
|
|
Mar 4
|
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
|
|
Jan 11
|
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
|
|
Jan 10
|
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
|
|
Dec 22
|
CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics
|
|
Jul 14
|
Exclusive-MoonLake Immunotherapeutics explores sale-sources
|